Follow The Filings

DGX Quest Diagnostics

Health Care, filed as QUEST DIAGNOSTICS INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.2%
  • $328K
  • 1 reduce

In 2026 Q3 Kentucky Trust trimmed Quest Diagnostics.

Who owns this now

Largest portfolio weights among holders, up to 0.2% (Kentucky Trust Co., Kentucky Trust). Not free-float ownership.

  1. Kentucky Trust Co. Reduce 0.16%

Who owns DGX

Sorted by value, long equity only, as of 2026 Q3.

History
Kentucky Trust Co., Kentucky Trust 0.16% Reduce −6.6% 1,406 $328K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by DGX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DGX insider trades
  • None no insider bought on the open market
  • $240K sold by 1 insider outside a trading plan
  • $36.5M sold by 7 insiders under 10b5-1 plans
  1. Gary M Pfeiffer Director
    Planned sale
    $292K 1,203 shares at $243.00 3.9% of stake
    Traded Oct 26 Filed Oct 28
    ↗
  2. J. E. Davis CEO
    Planned sale
    $2.4M 10,000 shares at $242.72 7.6% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  3. Michael E Prevoznik SVP & General Counsel
    Planned sale
    $5.5M 22,677 shares at $243.11 38% of stake
    Traded Aug 28 Filed Aug 31
    ↗
  4. Mark E Delaney SVP & Chief Commercial Officer
    Planned sale
    $376K 1,600 shares at $235.18 13% of stake
    Traded Jul 28 Filed Jul 29
    ↗
  5. Karthik Kuppusamy SVP, Clinical Solutions
    Planned sale
    $1.6M 8,147 shares at $200.00 38% of stake
    Traded Jun 4 Filed Jun 8
    ↗
  6. J. E. Davis CEO
    Planned sale
    $1.9M 10,000 shares at $194.14 7% of stake
    Traded Jun 1 Filed Jun 2
    ↗
  7. Catherine T. Doherty EVP, Regional Businesses
    Planned sale
    $1.1M 5,558 shares at $206.21 7.6% of stake
    Traded Mar 5 Filed Mar 6
    ↗
  8. Michael E Prevoznik SVP & General Counsel
    Planned sale
    $800K 3,878 shares at $206.21 9.4% of stake
    Traded Mar 5 Filed Mar 6
    ↗
  9. Patrick Plewman SVP for Diagnostic Services
    Planned sale
    $589K 2,855 shares at $206.21 16% of stake
    Traded Mar 5 Filed Mar 6
    ↗
  10. Catherine T. Doherty EVP, Regional Businesses
    Planned sale
    $131K 632 shares at $207.73 0.9% of stake
    Traded Mar 3 Filed Mar 4
    ↗
  11. Michael E Prevoznik SVP & General Counsel
    Planned sale
    $109K 526 shares at $207.73 1.4% of stake
    Traded Mar 3 Filed Mar 4
    ↗
  12. J. E. Davis CEO
    Planned sale
    $2.1M 10,000 shares at $212.52 7.9% of stake
    Traded Mar 2 Filed Mar 4
    ↗
  13. Patrick Plewman SVP for Diagnostic Services
    Planned sale
    $85K 410 shares at $207.73 2.6% of stake
    Traded Mar 3 Filed Mar 4
    ↗
  14. Catherine T. Doherty EVP, Regional Businesses
    Planned sale
    $294K 1,433 shares at $204.83 2.1% of stake
    Traded Feb 19 Filed Feb 20
    ↗
  15. Patrick Plewman SVP for Diagnostic Services
    Planned sale
    $196K 958 shares at $204.83 5.7% of stake
    Traded Feb 19 Filed Feb 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 35 stock grants, 32 share withholdings for taxes, 22 other transactions, 8 option exercises, 1 gift, and 1 sale to cover taxes.

Congress

8 members of Congress traded DGX in the last three years: 4 buys and 9 sales. 4 members listed it in 2025 annual reports.

All Congress trades
  1. Carol D. Miller R-WV-1Spouse Sell $15K–$50K Mar 10, 2025 filed Aug 13
  2. Julie Johnson D-TX-32Joint Buy $1K–$15K Oct 30, 2025 filed Aug 5
  3. Julie Johnson D-TX-32Joint Sell $1K–$15K Oct 30, 2025 filed Aug 5
  4. Alan Armstrong R-OK Buy $1K–$15K Mar 30 filed Jul 21
  5. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  6. Julia Letlow R-LA-5 Sell $1K–$15K Jul 24, 2025 filed Jan 13

SEC filings

Recent issuer filings from EDGAR, 7 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $9.25B $9.87B $11.04B
Gross profit * $3.05B $3.24B $3.66B
Gross margin * 33.0% 32.9% 33.2%
Net income $854M $871M $992M
Net margin * 9.2% 8.8% 9.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $2.37B $2.39B $2.38B
Total non-current assets * $11.65B $13.76B $13.85B
Total assets $14.02B $16.15B $16.22B
Total current liabilities $1.82B $2.17B $2.28B
Total equity $6.31B $6.78B $7.17B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.27B $1.33B $1.89B
Cash from investing -$1.06B -$2.55B -$0.631B
Cash from financing $0.16B $1.08B -$1.39B
Net change in cash $371M -$137M -$129M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.